scholarly journals The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States

2020 ◽  
Vol 23 (9) ◽  
pp. 967-977 ◽  
Author(s):  
Rachael Louise Slater ◽  
Yizhen Lai ◽  
Yichen Zhong ◽  
Haojie Li ◽  
Yang Meng ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Urothelial Carcinoma ◽  
The United States ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Advanced Urothelial Carcinoma ◽  
The Cost

1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1158-P
Author(s):  
ODETTE REIFSNIDER ◽  
PRATIK PIMPLE ◽  
MATTHEW J.D. STARGARDTER ◽  
SARAH BRAND ◽  
NIHAR DESAI ◽  
...  
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
The United States ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 8049-8049 ◽  
Author(s):  
B. K. Link ◽  
T. P. Miller ◽  
M. Byrtek ◽  
J. R. Cerhan ◽  
A. D. Zelenetz ◽  
...  
Keyword(s):  
United States ◽  
Observational Study ◽  
Follicular Lymphoma ◽  
The United States ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document